All In Biotech

Drug Trial Radar · NCT04274179

Ketogenic Diet for New-Onset Absence Epilepsy

A Prospective, Case-control Evaluation of Ketogenic Dietary Therapy for New-onset Childhood Absence Epilepsy

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 10, 2020

Primary completion

May 1, 2028

Study completion May 1, 2028

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ketogenic diet is a medical therapy for epilepsy that is used nearly predominantly for refractory epilepsy (after 2-3 drugs have been tried and failed). However, there is both published evidence for first-line use (infantile spasms, Glut1 deficiency syndrome) and also anecdotal experience (families choosing to change the child's (or the family' own) diet rather than use anticonvulsant medications). Childhood absence epilepsy (refractory) has been published as being responsive to ketogenic diet therapy by the investigators' group previously. This is a small, prospective, 3 month trial to assess if using a modified Atkins diet is a feasible and effective option for new-onset childhood absence epilepsy. The investigators will compare to a group of children in which the parents have declined and chose to start anticonvulsant medications.

Conditions

  • Absence Epilepsy
  • Ketogenic Dieting
  • Epilepsy, Absence

Interventions

  • Modified Atkins DietOther

    Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.

  • Absence epilepsy medicationsDrug

    At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in seizure frequencyTime frame: At 1 and 3 months post treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.